Avrobio to Merge With Tectonic Therapeutic in All-Stock Deal

Dow Jones01-30

By Will Feuer

Avrobio said it has agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets.

Tectonic is a privately-held biotechnology company developing GPCR, or G-protein coupled receptor-targeted therapeutic proteins. Once the deal is closed, the combined company will operate under the name Tectonic Therapeutic and trade on the Nasdaq under the ticker TECX.

Tectonic also separately has raised a $130.7 million private placement with a syndicate of new and existing investors, including TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners and others.

Once the deal closes, pre-merger Avrobio shareholders will own about 22.3% of the company while Tectonic shareholders will own about 40.2%.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

January 30, 2024 08:15 ET (13:15 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2407359856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-30 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2407359856","market":"other","top_or_hot":-1,"title":"Avrobio to Merge With Tectonic Therapeutic in All-Stock Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Will Feuer \n</p>\n<pre>\n \n</pre>\n<p>\n  Avrobio said it has agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets. \n</p>\n<p>\n  Tectonic is a privately-held biotechnology company developing GPCR, or G-protein coupled receptor-targeted therapeutic proteins. Once the deal is closed, the combined company will operate under the name Tectonic Therapeutic and trade on the Nasdaq under the ticker TECX. \n</p>\n<p>\n  Tectonic also separately has raised a $130.7 million private placement with a syndicate of new and existing investors, including TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners and others. \n</p>\n<p>\n  Once the deal closes, pre-merger Avrobio shareholders will own about 22.3% of the company while Tectonic shareholders will own about 40.2%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Will Feuer at Will.Feuer@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 30, 2024 08:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avrobio to Merge With Tectonic Therapeutic in All-Stock Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvrobio to Merge With Tectonic Therapeutic in All-Stock Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-30 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Will Feuer \n\n\n \n\n\n  Avrobio said it has agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets. \n\n\n  Tectonic is a ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2407359856","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2407359856","pubTimestamp":1706620500,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Avrobio said it has agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets.Tectonic is a privately-held biotechnology company developing GPCR, or G-protein coupled receptor-targeted therapeutic proteins. Once the deal is closed, the combined company will operate under the name Tectonic Therapeutic and trade on the Nasdaq under the ticker TECX.Tectonic also separately has raised a $130.7 million private placement with a syndicate of new and existing investors, including TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners and others.Once the deal closes, pre-merger Avrobio shareholders will own about 22.3% of the company while Tectonic shareholders will own about 40.2%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"Avrobio将在全股票交易中与大地构造治疗公司合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVRO":0.9},"content_text":"By Will Feuer \n\n\n \n\n\n  Avrobio said it has agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets. \n\n\n  Tectonic is a privately-held biotechnology company developing GPCR, or G-protein coupled receptor-targeted therapeutic proteins. Once the deal is closed, the combined company will operate under the name Tectonic Therapeutic and trade on the Nasdaq under the ticker TECX. \n\n\n  Tectonic also separately has raised a $130.7 million private placement with a syndicate of new and existing investors, including TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners and others. \n\n\n  Once the deal closes, pre-merger Avrobio shareholders will own about 22.3% of the company while Tectonic shareholders will own about 40.2%. \n\n\n \n\n\n  Write to Will Feuer at Will.Feuer@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2024 08:15 ET (13:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2407359856"}